Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents

Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents

Myeloproliferative neoplasms (MPN), are clonal hematopoietic stem cell (HSC) disorders driven by gain-of-function mutations in JAK2 (JAK2-V617F), CALR or MPL genes. MPN treatment options currently mainly consist of cytoreductive therapy with hydroxyurea and JAK2 inhibitors such as ruxolitinib and fe...

Full description

Bibliographic Details
Main Authors:	Jan Stetka, Radek C. Skoda
Format:	Article
Language:	English
Published:	Palacký University Olomouc, Faculty of Medicine and Dentistry 2021-03-01
Series:	Biomedical Papers
Subjects:	mpn myeloproliferative neoplasms jak2 mouse model pre-clinical models novel therapies
Online Access:	https://biomed.papers.upol.cz/artkey/bio-202101-0005_mouse-models-of-myeloproliferative-neoplasms-for-pre-clinical-testing-of-novel-therapeutic-agents.php

Similar Items

Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis
by: Ziqi Wan, et al.
Published: (2020-10-01)

The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up
by: Amina Kurtovic-Kozaric, et al.
Published: (2019-10-01)

Experimental Modeling of Myeloproliferative Neoplasms
by: Lucie Lanikova, et al.
Published: (2019-10-01)

Myeloproliferative Neoplasms Associated with Mutation in JAK2V617F and Tyrosine Kinase Inhibitors as Therapeutic Strategy
by: Kaveh Tari, et al.
Published: (2015-04-01)

Evaluation of Common Genetic Disorders in Myeloproliferative Neoplasms
by: Mehrdad Payandeh, et al.
Published: (2011-09-01)

Evaluation of Common Genetic Disorders in Myeloproliferative Neoplasms
by: Hoshang Yousefi, et al.
Published: (2011-10-01)

Evaluation of the Effect of <italic>NQO1 C609T (rs1800566)</italic> Gene Variations in Philadelphia-negative Myeloproliferative Neoplasms in Turkish Population
by: Ayşegül Başak Akadam Teker, et al.
Published: (2020-01-01)

CALRETICULIN IN MYELOPROLIFERATIVE NEOPLASMS: THE OTHER SIDE OF THE ALICE MIRROR
by: Lilian Varricchio, et al.
Published: (2014-07-01)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
by: Graeme Greenfield, et al.
Published: (2020-09-01)

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
by: Jason B. Kaplan, et al.
Published: (2016-01-01)

Effects of Interferon on PD-1/PD-L1 and Treg Expression in JAK2 V617F-positive Myeloproliferative Neoplasms
by: ZHANG Lijun, et al.
Published: (2019-01-01)

Non-Classic Myeloproliferative Neoplasms: Are We Really Aware of These Rare Diseases in Daily Practice
by: Serdal Korkmaz
Published: (2017-08-01)

The Mevalonate Pathway: A Potential Therapeutic Target for JAK2-driven Myeloproliferative Neoplasms
by: Griner, Lori Nicole
Published: (2013)

Murine Models of Myelofibrosis
by: Sebastien Jacquelin, et al.
Published: (2020-08-01)

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms
by: Vasundhara Sharma, et al.
Published: (2020-11-01)

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
by: Cecilia P. Marin Oyarzún, et al.
Published: (2019-06-01)

Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
by: Joseph A. Clara, et al.
Published: (2016-09-01)

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry
by: Judith Gecht, et al.
Published: (2021-08-01)

JAK2-positive Philadelphia-negative myeloproliferative neoplasms
by: Anjali Sharma, et al.
Published: (2011-01-01)

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
by: Steffen Koschmieder
Published: (2021-06-01)

The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?
by: Luisa Anelli, et al.
Published: (2018-04-01)

Clinical Discernment, Bone Marrow, and Molecular Diagnostics Are Equally Important to Solve the Phenotypic Mimicry among Subtypes of Myeloproliferative Neoplasms
by: Susann Schulze, et al.
Published: (2021-08-01)

A Broad Overview of Signaling in <i>Ph</i>-Negative Classic Myeloproliferative Neoplasms
by: Ana Guijarro-Hernández, et al.
Published: (2021-02-01)

The C allele of <it>JAK2 </it>rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
by: Ohyashiki Junko H, et al.
Published: (2012-01-01)

Hypothetical atopic dermatitis-myeloproliferative neoplasm (AD-MPN) syndrome
by: Toshiaki eKawakami, et al.
Published: (2015-08-01)

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
by: Paola Guglielmelli, et al.
Published: (2010-05-01)

CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
by: Lisa Pieri, et al.
Published: (2010-06-01)

The role of JAK2 abnormalities in hematologic neoplasms.
by: Mohammed Khalid Alabdulaali
Published: (2009-07-01)

Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association
by: Sarah Friis Christensen, et al.
Published: (2020-08-01)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
by: Lasse Kjær
Published: (2020-07-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Thrombosis among 1537 patients with JAK2V617F‐mutated myeloproliferative neoplasms: Risk factors and development of a predictive model
by: Yuhui Zhang, et al.
Published: (2020-03-01)

Targeted therapies for myeloproliferative neoplasms
by: Bing Li, et al.
Published: (2019-07-01)

Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
by: Daniel Arthur Corpuz Fisher, et al.
Published: (2021-06-01)

Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues
by: Marie Hautin, et al.
Published: (2020-08-01)

Arterial and Venous Thrombosis in Patients with Myeloproliferative Neoplasms
by: Lugyanti Sukrisman
Published: (2019-09-01)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
by: Morten Orebo Holmström, et al.
Published: (2020-07-01)

Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
by: Nicolas Chatain, et al.
Published: (2020-08-01)

A Drosophila model of myeloproliferative neoplasm reveals a feed-forward loop in the JAK pathway mediated by p38 MAPK signalling
by: Ana Terriente-Félix, et al.
Published: (2017-04-01)

Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms
by: Ngo Tat Trung, et al.
Published: (2019-06-01)